Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

PURPOSE: Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). The primary objectives of this phase IIa study included safety at the recommended phase II dose...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rudin, Charles M., Hann, Christine L., Garon, Edward B., Ribeiro de Oliveira, Moacyr, Bonomi, Philip D., Camidge, D. Ross, Chu, Quincy, Giaccone, Giuseppe, Khaira, Divis, Ramalingam, Suresh S., Ranson, Malcolm R., Dive, Caroline, McKeegan, Evelyn M., Chyla, Brenda J., Dowell, Barry L., Chakravartty, Arunava, Nolan, Cathy E., Rudersdorf, Niki, Busman, Todd A., Mabry, Mack H., Krivoshik, Andrew P., Humerickhouse, Rod A., Shapiro, Geoffrey I., Gandhi, Leena
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3715059/
https://ncbi.nlm.nih.gov/pubmed/22496272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3090
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars